Stock Information
symbol line chart

SENSSenseonics Holdings Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Timothy T. Goodnow

Location

Maryland, USA

Exchange

Nasdaq

Website

https://senseonics.com

Summary

Senseonics Holdings, Inc.

Company Info

CEO

Timothy T. Goodnow

Location

Maryland, USA

Exchange

Nasdaq

Website

https://senseonics.com

Summary

Senseonics Holdings, Inc.

AI Insights for SENS
5 min read

Quick Summary

Senseonics Holdings Inc. is a medical technology company focused on developing and commercializing continuous glucose monitoring systems for people with diabetes. Its core business is built around Eversense, an implantable CGM platform designed to measure glucose levels continuously over long periods. The company sells its products to diabetes patients through healthcare providers, prescribing clinicians, and distribution or commercialization channels in the United States, Europe, the Middle East, and Africa. Its main customers are people with diabetes who need reliable glucose monitoring, especially patients who may prefer fewer sensor replacements than traditional wearable CGM systems require. The company is headquartered in Maryland and operates as a small-cap Nasdaq-listed equity with a specialized focus on measuring and control equipment within the broader medical device market.

Strengths

•

Senseonics’ primary strength is its differentiated implantable CGM technology, especially the Eversense 365 one-year sensor.

•

A longer-duration sensor can offer a meaningful convenience advantage for patients who dislike frequent sensor changes or experience issues with traditional wearable CGMs.

•

The company has regulatory approvals in key markets and is expanding in the United States and Europe, which gives it a defined commercial pathway.

•

The integration with Sequel MedTech’s twiist automated insulin delivery system strengthens its relevance in connected diabetes care and automated insulin dosing.

•

Senseonics also benefits from improving sentiment in some analyst coverage and from revenue growth expectations that suggest the product may be gaining commercial traction.

Key Risks

•

The largest risks are execution risk, funding risk, and competitive risk.

•

Senseonics must prove that it can commercialize Eversense 365 efficiently after taking more commercialization responsibility in-house.

•

The company is still losing money, and higher operating expenses could require additional financing if revenue growth does not materialize quickly enough.

•

Competition from Dexcom, Abbott, Medtronic, and other diabetes technology companies could limit pricing power, market share, and provider attention.

What to Watch

During the most recent reported period, Senseonics showed evidence of stronger commercial traction around Eversense 365.
News reports cited Q3 revenue improving to about $8.1 million, while the fundamental data lists operating revenue of $14.483 million and total gross profit of $8.559 million for the reported period.
The company continued to operate at a loss, with total operating income of negative $35.988 million and net income of negative $36.705 million.
A major strategic event was the launch of the first integration between Eversense 365 and Sequel MedTech’s twiist automated insulin delivery system for type 1 diabetes.
Analyst commentary during the period remained mixed but generally more constructive, with some firms highlighting growth potential and others emphasizing funding and execution risks.

Price Drivers

•

The stock price is being driven mainly by expectations for Eversense 365 adoption, revenue growth, financing needs, and execution of the company’s commercial transition.

•

Recent news indicates improved analyst sentiment, a higher consensus price target in some coverage, and optimism around the one-year implantable CGM opportunity.

•

At the same time, the company remains unprofitable, with negative EPS, negative net income, and operating losses, so investors are highly sensitive to cash burn and funding developments.

•

Revenue growth guidance for 2026 of approximately $58 million to $62 million appears to be a major factor supporting bullish views, especially after 2025 revenue was reported around $35.3 million in the news.

•

The planned or completed reverse split, expanded debt financing, and commercialization shift away from Ascensia are also important because they affect liquidity, dilution risk, investor perception, and the company’s ability to scale sales.

Recent News

•

Recent news has centered on Senseonics’ launch of the Eversense 365 integration with Sequel MedTech’s twiist automated insulin delivery system.

•

This was described as the first pairing of a one-year implantable CGM with an automated insulin delivery platform.

•

Broad availability is expected by March 2026, and the launch could help Senseonics improve adoption among type 1 diabetes patients seeking automated dosing support.

•

Other news highlighted that Senseonics transformed its commercial strategy by taking Eversense 365 commercialization back from Ascensia and expanding direct-to-consumer and provider initiatives.

•

Analyst sentiment has improved in some reports, but coverage remains mixed because bullish revenue expectations are balanced by concerns about cash burn, funding needs, and commercial execution.

Market Trends

•

The diabetes technology market is benefiting from rising demand for continuous glucose monitoring, automated insulin delivery, and more personalized chronic disease management.

•

Patients and clinicians increasingly favor real-time data, connected devices, and systems that reduce daily treatment burden.

•

CGM adoption continues to expand beyond early adopters as reimbursement improves and awareness grows among providers and patients.

•

At the same time, the market is highly competitive, with large companies using scale, brand strength, and integrated ecosystems to defend share.

•

Senseonics is positioned within these favorable trends, but it must show that a long-duration implantable sensor can gain meaningful market share in a field dominated by established wearable CGM platforms.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on SENS

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@BrianHoward 6 months ago

Thoughts on the latest Senseonics results

Thoughts on the latest Senseonics results

i was looking at the recent growth numbers for Senseonics and it's impressive to see revenue up so much, even if the market reacted poorly to the losses. do you think is still a solid long-term bet despite the heavy investment phase they're entering? i'd love to hear how others are feeling about this one.

No more topics to show